Several medical representatives were investigated.

For some time in the late stage of the new domestic new crown outbreak, news about the compliance of medical representatives frequently appeared in the newspapers.
recently, a well-known junior a", "on the prohibition of the door (urgent) consultation area to receive medical representatives notice", said, because some medical representatives ignore the signs prohibited from entering, gathered at the door of a number of clinics, serious violations of relevant regulations, affecting the hospital order and environment, and easy to trigger the dissatisfaction and complaints of outpatient patients, please outpatient doctors refused to receive and advised.
notice clearly from the date of issuance of the notice, once verified, for the violation of this provision of the pharmaceutical representatives, by the relevant functional departments (pharmacy, procurement, medical equipment, etc.) to these pharmaceutical representatives of the suppliers in accordance with the hospital supplier management system.
days ago, the Communist Party of Hangzhou Xiaoshan District Discipline Inspection Commission public number "Xiaoshan Qingfeng" released: a well-known pharmaceutical enterprises, the former regional manager suspected of serious violations of the law, according to the Zhejiang Provincial Supervisory Commission, Hangzhou Municipal Supervision Commission designated jurisdiction, is currently under investigation by xiaoshan supervision committee.
according to industry sources, the cause of this matter is a well-known pharmaceutical company cancer product line of two representatives in the clinic to shoot a doctor's prescription, was seen by the head nurse and the police to take it away, further involved in the district manager.
the current treatment resulted in two medical representatives and regional managers having offered to leave, and the hospital suspended the company's drugs. Earlier in the
, according to The China Medical Daily, a hospital in Nantong City, during the outbreak, "captured" three non-compliant personnel, the parties are the manager of a pharmaceutical company and two employees.
the security services pointed out that in the hospital they were wearing white coats to conduct business, the incident caused the hospital to pay attention to and inform the enterprises involved.
in addition to the media attention, the Central Commission for Discipline Inspection since April has also repeatedly focused on pharmaceutical commercial bribery, gold sales and other issues. On June 27,
, the Central Commission for Discipline Inspection of the Communist Party of China (CPC) issued a headline article, "Observation, how to deal with bribery in the field of medicine - multi-party joint bribery and bribery together", pointed out that from the cases investigated in recent years, the pharmaceutical field bribery means show a variety of renovation, frequent frequency, huge amount of money and so on.
through the survey found that in some areas, drug "kickback" sales have become an open secret, the proportion of product rebates are negotiated in advance. On April 3,
, the Central Commission for Discipline Inspection published an article entitled "Selling pharmaceutical data, secretly doing medicine generation", revealing a case involving pharmaceutical sales staff for profit.
, Wang, a former pharmacy staff member of the First People's Hospital of a county in Zhejiang Province, first began selling hospital data because of his grasp of drug information, new drug entry and daily procurement power, and further expanded the unified layout, until the case, its illegal access to the unified data covers the county's more than 10 public hospitals (hospitals), covering hundreds of types of drugs.
on the above situation, there are not want to be named in the industry said to Saberblue, the new crown epidemic period, most of the pharmaceutical companies sales affected significantly, pharmaceutical representatives of the performance pressure is also greater, the impact of the current outbreak and slow, some pharmaceutical companies in order to complete the full-year performance target, but also raised the second half of the performance indicators, different from the performance pressure of previous years may lead some pharmaceutical representatives across the compliance of the bottom line.
the pharmaceutical purchase and sale chain, the whole body involved in the relevant compliance news of pharmaceutical representatives will cause widespread concern in the industry because the end of the sales behavior is often transmitted to suppliers, even pharmaceutical industry enterprises.
for example, at the end of last year, the official website of Sichuan Provincial People's Hospital issued a "Notice of Sichuan Provincial People's Hospital on the handling of non-compliant suppliers" shows that nine companies because of "hunting" hospital staff, commercial bribery, the hospital decided to make the following treatment: in accordance with the contract agreement with the supplier, immediately stop cooperation with the above-mentioned companies.
there is still a payment, deferred for two years.
put the companies on a "black list" of hospital procurement and permanently banned them from participating in hospital procurement.
blacklisted the legal representatives of the above-mentioned companies, executives involved in the case, and banned their associated companies from participating in hospital procurement.
once found that the "black list" on the people attached to other companies to participate in hospital procurement, immediately stop working with the company, stop payments, and the attached company into the "black list."
as the policies of various departments strengthen, the non-compliance of pharmaceutical representatives will also bring greater risks to pharmaceutical companies.
yesterday, the State Health Insurance Administration issued "guidance on the establishment of pharmaceutical prices and recruitment credit evaluation system (draft for comments)" for public comments.
documents clearly, from the date of the issuance of this Opinion, pharmaceutical enterprises (including pharmaceutical production license holders, pharmaceutical and medical supplies production enterprises, distribution enterprises with entrusted agent relations with production enterprises, as well as distribution enterprises) in the pricing, bidding, performance, marketing and other processes, through the list of list of breach of trust to obtain improper benefits, including the scope of pharmaceutical prices and credit evaluation.
the State Administration of Health Insurance to establish a list of medical prices and breach of trust, including but not limited to the list of credit rebates or other improper benefits in the purchase and sale of medicines (hereinafter referred to as "pharmaceutical commercial bribery"), abuse of market dominance, tax-related violations, improper price behavior, malicious breach of contract agreements, disturbing the centralized procurement order, etc.
under the new recruitment system, in response to the violations of pharmaceutical enterprises, recruitment agencies will take written reminders and warnings according to the credit rating of pharmaceutical enterprises, relying on centralized procurement platform to inform the purchaser of risk information, suspend the relevant drugs or medical supplies bidding network, suspend the supply and distribution of winning drugs or medical supplies qualification, public disclosure of information of breach of trust and other disposal measures. On the afternoon of July 24,
, the General Office of the National Health and Care Commission issued the Notice on the Issuance of the Special Action Program for the Construction of The Health Industry in 2020, which also made it clear that from July this year until the end of the year, the focus will be on the treatment of medical personnel to collect kickbacks, pharmaceutical companies illegal marketing and other acts.
for example: focus on the inspection of medical institutions practitioners to accept drugs, medical equipment, medical hygiene materials and other pharmaceutical products production, business enterprises or distribution personnel in various names, forms of rebate behavior.
medical personnel use any way and method for commercial purposes to count the medical practitioners and clinical departments about the amount of drugs, medical supplies, to facilitate the statistics of pharmaceutical marketers.
seriously investigate and punish the illegal marketing behavior of the distributors of pharmaceutical products and operating enterprises in medical institutions.
focus on the inspection of medical institutions outpatient, inpatient, pharmacy and other areas of pharmaceutical products production, business enterprises or distribution personnel illegally sell drugs, medical equipment to medical personnel, business negotiations.
medical institutions shall make full use of artificial intelligence or information-based means to provide early warning, monitoring and timely treatment of marketing activities in which distribution personnel of pharmaceutical products and enterprises enter medical institutions and engage with medical personnel.
at the end of the Notice, the National Health and Health Commission also stressed that, in addition to carrying out special treatment at the hospital end, it is also necessary to strengthen the comprehensive management of drug circulation, bidding, procurement, clinical use and other links, establish a bad record of commercial bribery in the field of pharmaceutical purchase and sale, and according to the provisions of the bad records of drugs, medical equipment and medical supplies production, operating enterprises in accordance with the law, guide and restrain the relevant industries enterprises and practitioners to comply with the relevant laws and regulations of the state, to form a good situation.
in addition to the medical insurance bureau from the recruitment end to establish a mechanism to combat bribery in medicine, the Health and Care Commission from the hospital use end to strengthen the strict investigation of the purchase and sale of medicine, more state departments are also on the purchase and sale of medicine with gold sales and other issues issued corresponding policy documents.
can be said that non-compliant pharmaceutical purchase and sale behavior for pharmaceutical representatives and pharmaceutical enterprises are a great risk, and with the improvement of the institutional mechanism, this risk will continue to increase, and finally quoted a commonly used phrase of foreign-funded enterprises, "the road ten million, compliance first."
.